Animal testing ban will help Evocutis
A EUROPEAN ban on testing cosmetic products on animals is likely to have major benefits for Yorkshire skin research business Evocutis.
The Wetherby-based group today announced bigger half year losses and smaller revenues as it moves from being a contract research business to selling its ‘living skin’ product LabSkin.
Evocutis launched LabSkin to the healthcare and cosmetic markets last September and it has already achieved contract research agreements with several multinationals.
LabSkin replaces the use of animals for testing, it emulates living skin tissue and is a high value research and product testing tool for the cosmetic and healthcare industries. To add to the current antimicrobial model, Evocutis is developing models to test anti-ageing and moisturising products.
In the six months to January 31 the firm firm made adjusted operating losses of £476,000 compared to £346,000 last year, on revenue of £226,000, compared to £344,000 last year.
The group had a cash balance of £1.030m at the half year end.
Earlier this month the European regulatory framework banning the testing of cosmetic ingredients on animals was completed and applies to products sold within the EU irrespective of whether the product was produced within or outside the EU.
